MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryDaily Refresh Schedule
Medical Laboratories Stocks$34.67
1.50%4:00PM 05/23/2022
The list of companies include BIOC-Biocept Inc, CDNA-Caredx Inc, CELC-Celcuity Inc, NTRA-Natera Inc, NVTA-Invitae Corp, OPGN-Opgen Inc, PROG-Progenity Inc, PSNL-Personalis Inc, VCYT-Veracyte Inc, WST-West Pharmaceutical Services, Inc.
Latest intraday update before market close @ 14:45:23 PM 05/24/2022
Summary :
Average return is down -4.0%
Median return is down -3.5%
0 out of 8 stocks are up (limited to those with intraday pricing feeds).

Aggregated price index

Aggregated price index with volume information

Summary:

  • Medical Laboratories stocks up 1.5% on average while median return up 0.9% in a day
  • Medical Laboratories stocks up 2.5% on average while median return up -1.1% in a week
  • Medical Laboratories stocks down 16.5% on average while median return down 17.7% in a month
  • When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.

Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.

Related Stocks

Click on + to show price series and click on ticker for stock detail page

Ticker
1 Day Return
1 Week Return
1 Month Return
PE Ratio
PE/G
P/B (mrq)
P/S (ttm)
Earning Growth
MarketCap
Short %
Held By Institutions %
RSI
Price Pattern
Resist Support
Days Since Channel Change
Channel Slope (daily rate %)
CELC17.5%
18.4%
-1.6%
-0.549.1099.6M7%25%52/\197-0.4%
GTH4.3%
-1.4%
-29.8%
4.26130.5M22%36-/\291-0.4%
BIOC2.8%
-4.5%
-12.4%
-0.182.181.3324.8M4%11%39/-\125-0.4%
NVTA1.7%
-1.1%
-31.3%
-1.79-1.92.7320.54846.1M16%82%35/\125-0.7%
WST0.9%
0.0%
-13.3%
33.851.7514.2111.18103%22.5B2%95%37/\At support125-0.2%
OPGN-0.1%
17.0%
-39.6%
1.8519.2818M1%7%35/-\107-0.6%
PSNL-1.6%
-9.2%
-26.2%
-2.40.796.8913.46198.1M9%87%34/\125-0.5%
NTRA-2.3%
15.1%
7.6%
-6.6124.1520.143.8B8%101%55/-\Above resistance125-0.6%
VCYT-2.3%
8.2%
-17.7%
2.5920.481.3B7%106%43\/-\125-0.5%
CDNA-7.5%
-4.0%
-21.8%
15.769.7620.861.3B11%101%40/\250-0.3%

* P/E and MarketCap are refreshed daily using IEX Cloud service. P/B, P/S, PEG, growth, short%, HelbyInstitute are refreshed weekly using Yahoo feeds. For latest stock stats please visit Yahoo Finance.

* Price Patter: / is upward trend, \ is downward trend, - is sideway. Click on the ticker to go to stock page to see Bayesian Trend model plot of the time series.

* Channel and change points are derived from Bayesian Trend model, where the channel slope is the growth rate while change points are those the model partition the time series.

Related ETFs (click on ticker for stock detail page)

leak data

  • 1M winners are : Winners for past month are $NTRA 7.6%
  • 1M losers are : Losers for past month are $CDNA -21.8%, $PSNL -26.2%, $GTH -29.8%, $NVTA -31.3%
  • 1W winners are : Winners for past week are $CELC 18.4%, $NTRA 15.1%, $VCYT 8.2%
  • 1W losers are : Losers for past week are $GTH -1.4%, $CDNA -4.0%, $BIOC -4.5%, $PSNL -9.2%
Pick two stocks to compare:

Correlation Analysis

Index correlation analysis

Correlation for the past month is 46.0%, for the past 3 months is 37.2%

In the past month for a 5 days rolling window, the highest corrrelation is 65.9%, the lowest correlation is 26.2%, the latest correlation is 38.6%

When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.

Among pairwise correlation, the highest correlation is 87.1% between NVTA and VCYT

The lowest correlation is -1.8% between PROG and PSNL

Stock news

    05/23/2022GTH
    Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022

    BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended March 31, 2022 on June 2, 2022 before the US market open. Management will host a conference call for invest

    05/23/2022BIOC
    Biocept Reports First Quarter 2022 Financial Results

    SAN DIEGO, May 23, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2022 and provides a business update.

    05/19/2022PROG
    Biora Therapeutics Announces New Patents for Targeted Therapeutics Platform

    Marks 29 Patents Worldwide Directed to Biora’s Device Localization TechnologySAN DIEGO, May 19, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced a new patent related to its Drug Delivery System (DDS) platform under development. The USPTO has issued U.S. Patent No. 10,835,152 entitled, “Electromechanical pill device with localization capabilities” and allowed U.S. Application No. 15/940,407 entitled, “Localizat

    05/17/2022WST
    Here's Why You Should Retain West Pharmaceutical (WST) Now

    West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

    05/17/2022CDNA
    In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 of 2 Patents Originally Asserted Against CareDx

    Natera Recycles Old IP for New Lawsuits SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Natera has just dropped one of their two patents originally asserted against CareDx. At the same time, Natera asserted two patents that are variations of the o

    05/16/2022PROG
    Biora Therapeutics to Participate in Upcoming H.C. Wainwright Global Investment Conference

    SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the Company’s management team will be presenting a corporate overview and participating in one-on-one meetings, upon request, with conference attendees at the upcoming H.C. Wainwright Global Investment Conference, which is taking place both virtually and in-person at the Fontainebleau Hotel in Miami, Florida, May 23 to 26, 2022. H.C. Wain

    05/16/2022BIOC
    Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q

    SAN DIEGO, May 16, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2022. The delay is related to the ongoing accounting review of Biocept’s financial statements as of and for the three months ended March 31, 2022, which ongoing review is a result of a change in circumstances at the U.S. Health Resources Services Administration (HR

    05/16/2022CELC
    Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates

    * Entered into $100 Million Private Placement Agreement * Finalized pivotal Phase 3 trial design for gedatolisib * Received FDA Fast Track designation for gedatolisib in HR+/HER2- advanced breast cancer * Management to host webcast and conference call today, May 16, 2022, at 4:30 p. ETMINNEAPOLIS, MN / ACCESSWIRE / May 16, 2022 / Celcuity Inc.